Skip to content

Andrew Biggerstaff

2 papers in the library · 45 citations · publishing 2018-2020

Papers

Sort Most recent Most cited

Evaluation of Biased and Balanced Salvinorin A Analogs in Preclinical Models of Pain

Frontiers in Neuroscience July 21, 2020 Kelly F Paton, Andrew Biggerstaff, Sophia Kaska et al.

In the search for safer, non-addictive analgesics, kappa opioid receptor (KOPr) agonists are a potential target, as unlike mu-opioid analgesics, they do not have abuse potential. Salvinorin A (SalA) is a potent and selective KOPr agonist, however, clinical utility is limited by the short duration of action and aversive side effects. Biasing KOPr signaling toward G-protein activation has been...

Kappa Opioid Receptor Agonist Mesyl Sal B Attenuates Behavioral Sensitization to Cocaine with Fewer Aversive Side-Effects than Salvinorin A in Rodents.

Molecules (Basel, Switzerland) October 11, 2018 Bronwyn M Kivell, Kelly F Paton, Nitin Kumar et al. 45 citations

The acute activation of kappa opioid receptors (KOPr) produces antinociceptive and anti-cocaine effects, however, their side-effects have limited further clinical development. Mesyl Sal B is a potent and selective KOPr analogue of Salvinorin A (Sal A), a psychoactive natural product isolated from the plant Salvia divinorum. We assessed the antinociceptive, anti-cocaine, and side-effects of...